Published in J Neurochem on March 01, 1999
Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem (2009) 5.76
Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain (2011) 2.13
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience (2010) 1.70
MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet (2012) 1.58
Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol (2002) 1.28
Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. J Biol Chem (2012) 1.22
A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. Brain (2010) 1.20
Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics. Nucleic Acids Res (2000) 1.17
The neurodegenerative mitochondriopathies. J Alzheimers Dis (2009) 1.14
The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol (2013) 1.05
Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis (2008) 1.04
Is tau ready for admission to the prion club? Prion (2012) 1.01
Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy. Am J Pathol (2001) 0.94
Monitoring tau-tubulin interactions utilizing second harmonic generation in living neurons. J Biomed Opt (2009) 0.92
Tau as a biomarker of neurodegenerative diseases. Biomark Med (2008) 0.91
Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol Commun (2014) 0.89
Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. BMC Neurosci (2008) 0.89
Silver diagnosis in neuropathology: principles, practice and revised interpretation. Acta Neuropathol (2007) 0.88
Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol (2015) 0.83
Alzheimer's disease pathologic cascades: who comes first, what drives what. Neurotox Res (2011) 0.83
Cortical Alzheimer type pathology does not influence tau pathology in progressive supranuclear palsy. Int J Clin Exp Pathol (2008) 0.80
Progressive supranuclear palsy. Mol Pathol (2001) 0.80
Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies. J Neurochem (2010) 0.80
Increased protein aggregation in Zucker diabetic fatty rat brain: identification of key mechanistic targets and the therapeutic application of hydrogen sulfide. BMC Cell Biol (2014) 0.79
Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci (2014) 0.76
Zebrafish models of Tauopathy. Biochim Biophys Acta (2010) 0.76
Hypoxia alters expression of zebrafish microtubule-associated protein tau (mapta, maptb) gene transcripts. BMC Res Notes (2014) 0.76
Prion-like Spreading in Tauopathies. Biol Psychiatry (2017) 0.75
Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: genetic, clinical and neuropathological analysis. Acta Neuropathol (2013) 0.75
Targeting mRNA for Alzheimer's and related dementias. Scientifica (Cairo) (2014) 0.75
Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition. Neurobiol Aging (2016) 0.75
Specific profile of tau isoforms in argyrophylic grain disease. J Exp Neurosci (2013) 0.75
Axodendritic sorting and pathological missorting of Tau is isoform specific and determined by axon initial segment architecture. J Biol Chem (2017) 0.75
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev (2000) 5.40
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology (1999) 3.49
Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Hum Mol Genet (2001) 2.08
Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J Neurol Sci (1986) 1.69
Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet (2001) 1.62
Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol (1999) 1.53
Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep (2000) 1.49
A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropathol (1992) 1.49
Study of the 10-nm-filament fraction isolated during the standard microtubule preparation. Biochem J (1980) 1.49
Abnormal tau species are produced during Alzheimer's disease neurodegenerating process. FEBS Lett (1989) 1.41
Alzheimer's disease: A beta or ApoE amyloidosis? Lancet (1995) 1.39
Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer's disease cases. Acta Neuropathol (1992) 1.38
Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol (1991) 1.28
Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol (1994) 1.26
Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol (1998) 1.25
Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology (2002) 1.22
Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Genet (1998) 1.20
Specific pathological Tau protein variants characterize Pick's disease. J Neuropathol Exp Neurol (1996) 1.18
Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: a quantitative analysis of six cases. Acta Neuropathol (1992) 1.18
Glial reaction in the hippocampal formation is highly correlated with aging in human brain. Neurosci Lett (1997) 1.17
The polypeptides of isolated brain 10nm filaments and their association with polymerized tubulin. Biochem J (1979) 1.16
Characterization of two pathological tau protein, variants in Alzheimer brain cortices. J Neurol Sci (1989) 1.12
Brain microvascular changes in Alzheimer's disease and other dementias. Ann N Y Acad Sci (1997) 1.09
Specific tau variants in the brains of patients with myotonic dystrophy. Neurology (1996) 1.08
Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet (1997) 1.08
Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder? J Neurol Neurosurg Psychiatry (1991) 1.07
Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. FEBS Lett (1997) 1.06
Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats. Exp Neurol (2007) 1.05
Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease. Acta Neuropathol (1996) 1.04
Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci Lett (1998) 1.04
Biochemical characterization of Tau proteins during cerebral aging of the lemurian primate Microcebus murinus. C R Acad Sci III (1995) 1.02
AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Brain Res Mol Brain Res (1996) 1.00
Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease. Neurology (2005) 1.00
Investigation of tubulin fibers formed during microtubule polymerization cycles. FEBS Lett (1977) 1.00
Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J Neurosci Res (2001) 0.99
Alzheimer's disease: a new evidence for common epitopes between microtubule associated protein Tau and paired helical filaments (PHF): demonstration at the electron microscope level by a double immunogold labelling. Virchows Arch A Pathol Anat Histopathol (1988) 0.98
Immunohistochemical identification of thrombospondin in normal human brain and in Alzheimer's disease. Am J Pathol (1992) 0.97
Proteasome inhibition and Tau proteolysis: an unexpected regulation. FEBS Lett (2005) 0.97
Correlation between microscopical changes and Tau 64 and 69 biochemical detection in senile dementia of the Alzheimer type. Tau 64 and 69 are reliable markers of the neurofibrillary degeneration. Acta Neuropathol (1990) 0.96
Alterations in neurofilament protein immunoreactivity in human hippocampal neurons related to normal aging and Alzheimer's disease. Neuroscience (1994) 0.95
Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome. Brain Res (1990) 0.94
Expression of ETS proto-oncogenes in astrocytes in human cortex. Brain Res (1988) 0.93
A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue. J Neurochem (1999) 0.93
Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Neurosci Lett (1996) 0.92
Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience (2003) 0.92
Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol (2006) 0.92
Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol (1999) 0.92
Observation of morphological relationships between angiopathic blood vessels and degenerative neurites in Alzheimer's disease. Virchows Arch A Pathol Anat Histopathol (1987) 0.91
ApoE synthesis in human neuroblastoma cells. Neurobiol Dis (1997) 0.90
Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease. Mol Psychiatry (2004) 0.90
Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: evidence for general cortical involvement. Acta Neuropathol (1994) 0.90
Alzheimer's disease: glycolytic pretreatment dramatically enhances immunolabeling of senile plaques and cerebrovascular amyloid substance. Lab Invest (1989) 0.90
Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide. Brain Res (1993) 0.89
Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. Am J Pathol (1995) 0.89
Immunocytochemical characterization of Tau proteins during cerebral aging of the lemurian primate Microcebus murinus. C R Acad Sci III (1995) 0.89
The immunohistochemical evidence of amyloid diffuse deposits as a pathological hallmark in Alzheimer's disease. J Gerontol (1991) 0.88
Synthesis and regulation of apolipoprotein E during the differentiation of human neuronal precursor NT2/D1 cells into postmitotic neurons. Exp Neurol (2000) 0.88
Neuronal localization of copper-zinc superoxide dismutase protein and mRNA within the human hippocampus from control and Alzheimer's disease brains. Free Radic Res Commun (1991) 0.87
Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett (1998) 0.87
Neurofibrillary tangles in Gerstmann-Sträussler-Scheinker syndrome with the A117V prion gene mutation. J Neurol Neurosurg Psychiatry (1997) 0.87
Rapid tau protein dephosphorylation and differential rephosphorylation during cardiac arrest-induced cerebral ischemia and reperfusion. J Cereb Blood Flow Metab (2000) 0.87
Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neurosci Lett (1997) 0.86
Neuroimaging outcomes in clinical trials in Alzheimer's disease. J Nutr Health Aging (2009) 0.86
Parkinson's disease and Alzheimer's disease: neurodegenerative disorders due to brain antioxidant system deficiency? Adv Exp Med Biol (1990) 0.86
Mapping of neurofibrillary degeneration in Alzheimer's disease: evaluation of heterogeneity using the quantification of abnormal tau proteins. Acta Neuropathol (1992) 0.86
Neuronal-specific expression of human copper-zinc superoxide dismutase gene in transgenic mice: animal model of gene dosage effects in Down's syndrome. Brain Res (1991) 0.85
Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide. Brain Res (1993) 0.85
Dementia in Parkinson's disease: biochemical evidence for cortical involvement using the immunodetection of abnormal Tau proteins. Ann Neurol (1993) 0.85
A double-labeling immunohistochemical study of tau exon 10 in Alzheimer's disease, progressive supranuclear palsy and Pick's disease. Acta Neuropathol (2000) 0.84
[Alzheimer's disease: study of the distribution of tau proteins constituting helical filament pairs in human central nervous tissue]. C R Acad Sci III (1988) 0.84
The proprotein convertase PC2 is involved in the maturation of prosomatostatin to somatostatin-14 but not in the somatostatin deficit in Alzheimer's disease. Neuroscience (2003) 0.83
Cortical angiopathy in Alzheimer's disease: the formation of dystrophic perivascular neurites is related to the exudation of amyloid fibrils from the pathological vessels. Virchows Arch A Pathol Anat Histopathol (1988) 0.83
Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies. Neuropathol Appl Neurobiol (2004) 0.83
Intermediate filament proteins in mouse brain cells cultured in the presence or absence of fetal calf serum. Exp Cell Res (1982) 0.83
Two-dimensional characterization of paired helical filament-tau from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications. J Neurochem (1997) 0.83
Presence of abnormally phosphorylated Tau proteins in the entorhinal cortex of aged non-demented subjects. Neurosci Lett (1992) 0.83
Dystrophic peptidergic neurites in senile plaques of Alzheimer's disease hippocampus precede formation of paired helical filaments. Brain Res (1989) 0.83
Characterization of mammalian neurofilament subunits by circular dichroism. Biochim Biophys Acta (1982) 0.83
Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders. Acta Neuropathol (1994) 0.82
Evidence for apolipoprotein E epsilon 4 association in early-onset Alzheimer's patients with late-onset relatives. Am J Med Genet (1995) 0.82
Alzheimer-specific epitope of AT100 in transfected cell lines with tau: toward an efficient cell model of tau abnormal phosphorylation. Neurosci Lett (1998) 0.82
Anti-PHF antibodies: an immunohistochemical marker of the lesions of the Alzheimer's disease. Characterization and comparison with Bodian's silver impregnation. Virchows Arch A Pathol Anat Histopathol (1985) 0.82
Coexistence of reactive plasticity and neurodegeneration in Alzheimer diseased brains. Histol Histopathol (2004) 0.82
Alzheimer's disease: microtubule-associated proteins 2 (MAP 2) are not components of paired helical filaments. FEBS Lett (1989) 0.82
Progressive transformation of the cytoskeleton associated with normal aging and Alzheimer's disease. Brain Res (1992) 0.82
Synthesis of apolipoprotein E (ApoE) mRNA by human neuronal-type SK N SH-SY 5Y cells and its regulation by nerve growth factor and ApoE. Neurosci Lett (1999) 0.82
Non-Alzheimer degenerative dementias. Curr Opin Neurol (1998) 0.81
Pathological tau phenotypes. The weight of mutations, polymorphisms, and differential neuronal vulnerabilities. Ann N Y Acad Sci (2000) 0.81
Applications of chemical cleavage procedures to the peptide mapping of neurofilament triplet protein bands in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem (1986) 0.81